tesamorelin
Growth hormone secretagogues · 19 suppliers · $1.80 to $11.99 per mg · 24 registered studies · 121 indexed papers
This page holds two records that were compiled separately. The research figures below come from the public registries named under each one, each read on the date printed beside it. The supplier prices at the foot were read on the suppliers own sites on the dates in that table. Nothing here was produced by this publication measuring anything.
Identity and computed properties
PubChem holds this compound as CID 16137828, molecular formula C221H366N72O67S, average mass 5136 daltons and monoisotopic mass 5132.7166 daltons, read on 2026-09-19. Those masses are computed from the deposited structure and were not measured on any material, so they are the expected value an identity check compares against rather than evidence about any vial.
The title that record carries for the CID is Tesamorelin. Its synonym list runs to 22 entries.
Receptors the literature describes
No published paper this search reached describes a receptor this compound acts at.
The registered trial record
An intervention search of clinicaltrials.gov for the term tesamorelin, read on 2026-09-19, returned 24 registered studies: 2 phase 1, 10 phase 2, 2 phase 3, 2 phase 4 and 8 recorded with no phase.
Massachusetts General Hospital is lead sponsor on 9 of the 24 records. The remaining 15 name 8 other organizations.
On the date read, the statuses those records carried were 14 completed, 4 terminated and 3 withdrawn, among others.
The earliest record the search returns is NCT00123253, first submitted 2005-07-20. That date is a floor, not an origin: earlier work may sit in the registry under a code number this search term does not match.
Registry counts measure registration, not knowledge.
The publication record
PubMed answered 121 records for the term tesamorelin on 2026-09-19. Of those, 28 carry a clinical-trial publication type, and 3 of those carry Clinical Trial, Phase III. 36 carry the publication type Review, which is other people reading the rest.
PubMed counts measure indexing, so work in venues it does not index is invisible to this figure. The term that produced it is printed above so it can be run again.
Regulatory status
The Drugs@FDA database holds application BLA 022505 under this name, sponsor THERATECHNOLOGIES. Its listed products are marked Prescription in the same database.
Findings, as published reports recorded them
This block was compiled and no finding from a named publication was reached.
Adverse events, as published reports recorded them
This block was compiled and no adverse event from a named publication was reached.
Spontaneous report databases are not used on this page. A count of reports carries no denominator, so it cannot be read as a rate and is not printed as one.
Who it is not given to
labelFour groups must not be given Egrifta SV. People whose pituitary gland or hypothalamus has been damaged, whether by surgery, a tumour, radiation to the head or a head injury. People with active cancer, and any earlier cancer must be inactive with its treatment finished first. Anyone allergic to tesamorelin. And pregnant women.EGRIFTA SV label · read 2026-09-19
labelThe label gives its own reason for the pregnancy rule. Shrinking visceral fat offers a pregnant woman no benefit, and it could harm the baby.EGRIFTA SV label · read 2026-09-19
Egrifta SV is a prescription medicine for a specific condition. Powder sold as tesamorelin is not that product.read 2026-09-19
Every row is a price read on that supplier's own site, divided by the milligrams it buys. Cheapest first, which is not a ranking of quality: the columns beside the rate show what this publication could confirm about the evidence behind it. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Vendor comparison
| Per mg | Price | Supplier | Certificate checkable | Caution on record | What the figure is |
|---|---|---|---|---|---|
| $1.80per mg | $180.0010mg × 10 vials | reta-peptiderecord → | not transcribed | not transcribed | 10-vial kit, 10mg per vialread 2026-08-20 |
| $4.16per mg | $416.0010mg × 10 vials | GreyLabsrecord → | not transcribed | not transcribed | 10-vial kit; mg is the per-vial sizeread 2026-08-25 |
| $5.50per mg | $54.9910mg | Panda Peptidesrecord → | not transcribed | not transcribed | discounted from 57.99read 2026-08-23 |
| $6.50per mg | $65.0010mg | Polaris Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-20 |
| $6.50per mg | $65.0010mg | Tex Peptidesrecord → | you can check it | Both retatrutide pages print BPC-157 identifiers verbatim, including the formula, sequence and CAS number, while the vendor's own report reads Retatrutide. The semaglutide and tirzepatide pages are correct. | single vial current priceread 2026-08-24 |
| $6.80per mg | $68.0010mg | Ameano Peptides (.com)record → | not transcribed | not transcribed | single vial current priceread 2026-08-25 |
| $7.00per mg | $69.9910mg | Pepora Labsrecord → | not transcribed | not transcribed | discounted from 99.99read 2026-08-23 |
| $7.00per mg | $70.0010mg | Full Scale Peptidesrecord → | not transcribed | not transcribed | discounted from 80.00read 2026-08-25 |
| $7.50per mg | $75.0010mg | Aspire Peptidesrecord → | not transcribed | not transcribed | single vial current price, discounted from list 159.00read 2026-08-25 |
| $7.60per mg | $38.005mg | Biotech Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-17 |
| $7.90per mg | $79.0010mg | NeuroPept Labsrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-26 |
| $8.90per mg | $89.0010mg | Peptirarecord → | not transcribed | not transcribed | single vial current priceread 2026-08-20 |
| $8.99per mg | $89.9510mg | Koi Aminosrecord → | not transcribed | not transcribed | single vial current price, single stated sizeread 2026-08-26 |
| $9.00per mg | $90.0010mg | Secra Labsrecord → | you can check it | 16 of the 21 products carry no published certificate. | single vial current priceread 2026-08-24 |
| $9.90per mg | $99.0010mg | Restore Peptidesrecord → | you can check it | One product page renders a Certificate of Analysis panel with no document behind it. | single vial current priceread 2026-08-24 |
| $9.99per mg | $99.9010mg | Excalibur Peptidesrecord → | you can check it | Neither published retatrutide certificate names this vendor. The issuing laboratory's own register shows the accession filed against a different client, while this vendor's own certificates sit under a separate prefix. | discounted from 104.80read 2026-08-24 |
| $10.00per mg | $50.005mg | Arcane Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-25 |
| $11.00per mg | $109.9910mg | Lab Trust Peptidesrecord → | not transcribed | not transcribed | single vial current price in USD, discounted from 129.99read 2026-08-26 |
| $11.99per mg | $59.955mg | Atomix Researchrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-23 |
Read between 2026-08-17 and 2026-08-26. Prices move and these were read once.
Sources
Registered study counts, phases, lead sponsors and first-submitted dates: the clinicaltrials.gov public API, one intervention search on the term printed above, read 2026-09-19. Indexed paper counts and publication types: PubMed, the term printed above and that term narrowed by publication type, read 2026-09-19. Formula and computed mass: PubChem, the CID printed above, read 2026-09-19. Application status: the Food and Drug Administration Drugs@FDA database through the agency public endpoint, read 2026-09-19.
The dates in the paragraph above are the dates those fetches ran, stamped in UTC. The dates in the list below are the dates a person read each record. The same record can carry both, a day apart, when a fetch ran after midnight UTC.
- PubChem compound record, CID 16137828 read 2026-09-19
- Food and Drug Administration label record, openFDA drug label endpoint, tesamorelin read 2026-09-19